Universal Express to Move Its Corporate Headquarters

2 November 1999

Universal Express to Move Its Corporate Headquarters and is No Longer Terminal (Drive)

    PLAINVIEW, N.Y.--Nov. 2, 1999--Universal Express, Inc. (OTC:USXP) today announced its plans to move its 13 year old 20 South Terminal Drive, Plainview Corporate offices to 1350 Broadway in New York City by December, 1999 and to also move immediately its new International Headquarters to 1 Central Park West at the Trump International Tower.
    "As Universal Express has positioned itself in the vast shipping and E-commerce fulfillment market, it now literally moves itself into the true center of New York," stated Richard A. Altomare, President and CEO.
    "Our new International offices at the Trump International Tower will concentrate on our newest program called `Buyer WeCare' - an E-commerce worldwide auction program utilizing the membership of its private postal network to provide quality control in the virtual world."
    Universal Express, Inc. (USXP) owns and operates several subsidiaries in the packaging and shipping business including SkyWorld International Couriers and the Private Postal Network.com (PPN) which provides logistical services and cost-effective delivery of goods worldwide. USXP's other subsidiaries are engaged in advertising (Images), entertainment (Manhattan Concierge) and additional support services (Packaging Plus Services, UniqueNet.com, WorldPost Network.com and the Postal Business Center Network (PBC Network.com)).
    Universal Express's web site address is: http://www/usxp.com
    Investor Relations, call James Stock, President of Stock Enterprises at (702) 614-0003

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies or products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.